In April 2023, Novo Nordisk submitted a biologics license application to the US Food and Drug Administration for once-weekly insulin icodec for T2D treatment based on the ONWARDS program, and the decision is expected in April of 2024 [11]. Here, INS is linked to type 2 diabetes mellitus.